	US 11,713,290 B2
	Cycloheptylamine derivatives as anti-diabetic agents
Abdu Adem, Al Ain (AE); Shaikha S. Al Neyadi, Al Ain (AE); Ibrahim M. Abdou, Al Ain (AE); Alaa A. Salem, Al Ain (AE); and Naheed Amir, Al Ain (AE)
Assigned to UNITED ARAB EMIRATES UNIVERSITY, Al Ain (AE)
Filed by UNITED ARAB EMIRATES UNIVERSITY, Al Ain (AE)
Filed on Jul. 27, 2021, as Appl. No. 17/386,279.
Application 17/386,279 is a division of application No. 16/866,856, filed on May 5, 2020, granted, now 11,091,426.
Prior Publication US 2021/0355074 A1, Nov. 18, 2021
Int. Cl. C07C 211/35 (2006.01); C07C 279/26 (2006.01); C07C 317/42 (2006.01); C07C 279/16 (2006.01); C07D 401/04 (2006.01); C07D 239/48 (2006.01)

CPC C07C 211/35 (2013.01) [C07C 279/16 (2013.01); C07C 279/26 (2013.01); C07C 317/42 (2013.01); C07D 239/48 (2013.01); C07D 401/04 (2013.01)]

4 Claims

1. A method of treating diabetes comprising administering a therapeutically effective amount of Cycloalkylamine derivatives, comprising compounds selected from the group consisting of cycloheptylamine hydrochloride, cycloheptylamine hydrobromide, cyclopentylamine hydrochloride, cyclohexylamine hydrochloride, or a pharmaceutically acceptable salt thereof to a patient in need thereof.